Seeing the light: opsin

The second structure of Christmas is the membrane protein opsin, which allows us to perceive light.

Proteins that control the information going in and out of our cells are harder to crystallise than run-of-the-mill globular proteins, as they have both water-loving and fat-loving parts and are tricky to mass produce. Opsin, our second structure of Christmas, is one such molecule. It is situated on a special membrane in a specialised cell at the back of our eyes, and senses light.

Continue reading “Seeing the light: opsin”

The shape of our tears: lysozyme

If there is one protein we can say we know inside and out, it is the humble lysozyme, which we carry in our tears. This is my first Structure of Christmas for 2016.

Nowadays, we can see the position of atoms as if we had vision millions of times sharper than human eyes allow. This is the gift of structural biology – the science of determining the 3D structures of molecules and correlating them with function. Structural biology gives us something more powerful than human vision, as the wavelength of ‘visible’ light is too long to resolve the position of atoms.

Continue reading “The shape of our tears: lysozyme”

GA4GH: What? Why? How?

In August 2016, I was offered the position of Chair of the Global Alliance for Genomics and Health (GA4GH), and am delighted to accept. To give a little more background to the announcement going out today, and to provide some answers to personal questions, I’ve written a bit of Q&A.

In this post I answer the three questions I am most frequently asked about the GA4GH, namely: What on Earth is it? Why am I becoming Chair? And how on earth do I find the time for these things? What is the Global Alliance for Genomics and Health?

Continue reading “GA4GH: What? Why? How?”

Sharing clinical data: everyone wins

Patients who contribute their data to research are primarily motivated by a desire to help others with the same plight, through the development of better treatments or even a cure. Out of respect for these individuals, and to uphold the fundamental tenets of the scientific process, I’d like the clinical trials community to shift its default position on data sharing and reuse to align to data availability on publication, similar to the life science community. This will enable more robust, rigorous research, create new opportunities for discovery and build trust between patients and scientists.

Continue reading “Sharing clinical data: everyone wins”

Advice on Big Data Experiments and Analysis, Part I: Planning

Biology has changed a lot over the past decade, driven by ever-cheaper data gathering technologies: genomics, transcriptomics, proteomics, metabolomics and imaging of all sorts. After a few years of gleeful abandon in the data generation department, analysis has come to the fore, demanding a whole new outlook and on-going collaboration between scientists, statisticians, engineers and others who bring to the table a very broad range of skills and experience.

Continue reading “Advice on Big Data Experiments and Analysis, Part I: Planning”

In defence of model organisms

I have written about the rise of human as a first-class model organism, and am an enthusiastic user of this outbred, large vertebrate, which can walk right into pre-funded phenotyping centres (hospitals). However, some scientists are (somewhat flippantly) predicting ‘the demise of all non-human model organisms’ completely, only conceding the necessity for using mouse in impossible-in-human verification experiments. Although such positions tend to be put forward in jest, their underlying argument resonates: given our obsession on human health, and how much we can do humans – with broad outbred genetics, iPSC cell lines and organoids – why should we bother with other systems?

Continue reading “In defence of model organisms”